bioAffinity Technologies Inc. has announced the issuance of a U.S. patent for their innovative cancer therapy, which utilizes small interfering RNAs (siRNAs) to target and silence specific cell surface receptors, CD320 and LRP2. This approach has shown promise in selectively killing cancer cells across various types, including lung, breast, prostate, brain, and skin cancers, while sparing normal cells. The company also received notification of a patent grant from the China National Intellectual Property Administration, signaling potential global impact for their therapeutic advancements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.